Necroptosis as a key player in cervical cancer progression and management: a systematic review and transcriptomic cross-study consensus analysis.
Seth-Frerich Fobian, Eric Eldering, Jacqueline Tromp et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and transcriptomic cross-study consensus analysis examined published evidence on necroptosis in cervical cancer, including seven prognostic gene models and exploratory analyses of overlapping genes and pathways. Across studies, seven necroptosis-related genes were identified, with links to mitochondrial transport and permeability, reactive oxygen species generation, and inflammatory signaling. Necroptosis activation was generally associated with greater immune infiltration and activation and with improved prognosis. The authors propose that necroptotic signaling could be explored as a way to enhance immunotherapy responses, while emphasizing that the findings provide a basis for future experimental validation rather than established treatment guidance.
Key findings
- The review assessed seven published necroptosis-related prognostic models and compared eight overlapping genes and their reported risk-score coefficients.
- Seven necroptosis-related genes were identified across studies, with many linked to mitochondrial regulation, reactive oxygen species, and inflammatory signaling.
- Necroptosis activation was generally associated with enhanced immune infiltration and activation, alongside improved prognosis.
Why it matters
Cervical tumors that are immunologically cold may respond poorly to immunotherapy. The review brings together transcriptomic and prognostic findings suggesting that necroptosis is associated with a more active tumor immune environment. This offers a biologically plausible direction for research into combination strategies, but the evidence summarized is not sufficient to establish that manipulating necroptosis improves clinical outcomes.
What to keep in mind
The analysis synthesizes published prognostic models and exploratory transcriptomic findings; the authors state that experimental validation and therapeutic development remain future work.